- Cowen has raised Impel NeuroPharma Inc's IMPL price target to $55 from $35, with an Outperform rating, after the FDA approved Trudhesa for the acute treatment of migraine.
- The analyst sees more than 100% upside for the stock.
- Related Content: FDA Gives Nod To Nasal Spray Migraine Treatment From Impel NeuroPharma.
- The "clean label" came in line with expectations, analyst Ken Cacciatore tells investors in a research note.
- The analyst believes Trudhesa's "differential delivery" should provide a "much-needed" acute migraine option into this "extremely" large market.
- Price Action: IMPL stock is up 17.2% at $27.10 during the market session on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: Analyst ColorLong IdeasNewsHealth CarePrice TargetSmall CapFDAAnalyst RatingsMoversTrading IdeasGeneralBriefsmigraine
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
